A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012

Learn more:

• clinicaltrials.gov: #NCT02639065
• See Study Page on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.